Table 1.

Phase II trials to determine pCR and MPR after neoadjuvant ICI or ICI plus chemotherapy in patients with resectable and operable stage I-III lung cancers.

	Author(s)	Agent(s)	MPR% (95% CI)	pCR% (95% CI)
Johns Hopkins University/Memorial Sloan Kettering N=21	Forde and Chaft(10)	Nivolumab	43% (21 to 66)	14% (4 to 34)
LCMC3 Lung Cancer Mutation Consortium - USA N=82	Kwiatkowski(12)	Atezolizumab	18% (11 to 28)	5% (2 to 12)
NEOSTAR MD Anderson N=44	Cascone(13)	Nivolumab + Ipilimumab	25% (14 to 40)	18% (9 to 32)
NADIM Spanish Lung Cancer Group N=30	Provencio(14)	Nivolumab + Paclitaxel Carboplatin	80% (64 to 91)	75% (4 to 76)
Columbia University New York/MGH N=30	Shu(11)	Atezolizumab + Paclitaxel Carboplatin	57% (36 to 76)	33% (18 to 52)
Duke/Dartmouth/Mayo N=25	Ready(15)	Pembrolizumab	28% (12 to 49)	8% (1 to 26)